---
title: "Varegacestat (AL102) in Desmoid tumors: RINGSIDE part A"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: RINGSIDE part A. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 95 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence/ringside-part-a"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: RINGSIDE part A

<a id="heading-3.1.2"></a>

## 3.1.2 RINGSIDE Part A

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Study purpose: safety, preliminary efficacy, and selection of the phase III dose regimen

> “We report results of the phase II open-label, multicenter, randomized, dose-finding study to evaluate safety and preliminary efficacy and select a phase III dose regimen.”
> “What is the optimal dose regimen of oral varegacestat in adults with progressing desmoid tumors, based on safety and antitumor activity?”
> “We evaluated three varegacestat dose regimens in adults with progressing DTs.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.1-2"></a>

#### Registry objective

> “The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.1-3"></a>

#### Post hoc analysis objective: treatment response in key subgroups

> “We evaluated treatment response in key subgroups.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-3.1.2.1-4"></a>

#### Exploratory analysis objective: T2-weighted signal intensity, tumor volume, and exposure-response

> “We report exploratory analyses of T2W signal intensity, tumor volume and exposure-response (E-R) in the RINGSIDE Phase 2 study”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Screening and enrollment from October 2021 to July 2022 at 21 academic medical centers in seven countries

> “Between October 6, 2021, and July 15, 2022, 52 participants were screened, of whom 42 were enrolled (14 in each dose arm) at 21 academic medical centers in Australia, Korea, Spain, Israel, the Netherlands, the United Kingdom, and the United States (Fig 1).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.2-2"></a>

#### Transition to the open-label extension from October 2022 to May 2023 and data as of January 6, 2025

> “Between October 4, 2022, and May 30, 2023, 29 (69.0%) participants transitioned to the open-label extension, where all received 1.2 mg once daily. As of January 6, 2025, 12 participants remained on treatment.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.2-3"></a>

#### Study start and data cutoff

> “Study start: Oct. 6, 2021 | Data cutoff: Jan. 6, 2025”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.2-4"></a>

#### Enrollment completed as of March 2022 and interim data as of January 3, 2023

> “Enrollment of all 42 patients into Phase 2 was completed as of March 2022. As of January 3, 2023, median time on study was 10.5 months (range 0.8 – 14.7) and 30 patients (71.4%) were still on study, 10 (23.8%) of whom rolled over to the OLE.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="topic-3.1.2.2-5"></a>

#### Interim data as of April 10, 2024

> “As of April 10, 2024, median time on treatment was 25.4 mo (range 1 – 29); 21 pts (50%) were still on treatment.”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.2-6"></a>

#### Registry dates and study identifier

| Field | Quoted record |
| --- | --- |
| First posted | “2021-05-04” |
| Study start (actual) | “2021-09-01” |
| Other study ID | “AL-DES-01” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Open-label, randomized, dose-finding phase II part of a phase II/III trial

> “RINGSIDE phase II was an open-label, randomized, dose-finding trial of varegacestat in adults with histologically confirmed DT and disease progression.”
> “RINGSIDE was a phase II/III clinical trial (ClinicalTrials.gov identifier: NCT04871282) to evaluate the safety and efficacy of varegacestat (Immunome, Inc, Bothell, WA) for treatment of progressing DTs.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.3-2"></a>

#### Registry design: Part A dose regimen finding and Part B placebo-controlled study

> “This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting of 2 parts. Phase2/Part A is an open-label, dose regimen finding study; Phase3/Part B is a double blind, placebo-controlled study and Open Label Extension utilizing the dose regimen selected in Phase2/Part A.”
> “RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.3-3"></a>

#### Dose selection after the last week 16 MRI and entry into the open-label extension

> “Phase III dose selection was based on emerging safety and tolerability data after the last patient completed the week 16 magnetic resonance imaging (MRI) scan, and the key secondary end point of volume change could be assessed. After phase III dose selection, participants could enter an open-label extension study, where all received the selected phase III dose.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.3-4"></a>

#### Independent data monitoring committee

> “An independent data monitoring committee reviewed safety parameters at regular intervals and efficacy data to assess benefit/risk and approved the selected dose.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.3-5"></a>

#### Seamless phase 2/3 design

> “Based on these data and responses demonstrated with other GSIs, Ayala designed a seamless Phase 2/3 study called RINGSIDE to specifically evaluate the activity of varegacestat in participants with progressing desmoid tumors who required therapy.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.2.3-6"></a>

#### MRI schedule in the phase 2 part and the open-label extension

> “Scans at week 16 and every 12 weeks thereafter”
> “Scans every 12 weeks”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.3-7"></a>

#### Transition to the open-label extension between week 36 and week 76

> “Week 36–76”
> “Open-label Extension (OLE) (N=29)”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="topic-3.1.2.3-8"></a>

#### Sponsors: Immunome and Ayala Pharmaceuticals

> “Supported by Immunome, Inc.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

> “The RINGSIDE study (NCT04871282) was sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Inclusion criteria: adults with histologically confirmed, progressing desmoid tumors

> “Eligible participants were 18 years and older with histologically confirmed DTs and investigator-assessed disease progression, defined as unidimensional growth of ≥10% (sum of diameters of target lesion[s]) within 18 months of the screening MRI or DT-related pain not adequately controlled with nonopioid medication. Participants were either treatment-naïve or previously treated with at least one measurable lesion amenable to volume measurements by MRI.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.4-2"></a>

#### Registry inclusion criteria for Part A

> “Inclusion Criteria Part A:”
> “At least 18 years of age (inclusive) at the time of signing the informed consent form (ICF).”
> “Disease progression, assessed locally by the investigator, defined as having at least one of the following:”
> “Unidimensional growth of desmoid tumor(s) by ≥10%, using the sum of the largest diameters of target lesion(s), within 18 months of the screening MRI”
> “Having desmoid tumor-related pain that is not adequately controlled with nonopioid medication”
> “At least 1 measurable lesion amenable to volume measurements by MRI at screening”
> “Treatment naïve subjects for whom, in the opinion of the investigator, the IP is deemed appropriate, OR”
> “Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy)”
> “Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.4-3"></a>

#### Exclusion criteria

> “Exclusion criteria included malignancy diagnosed in the past 2 years (exceptions defined in the protocol), Eastern Cooperative Oncology Group performance status ≥2, GI disease associated with diarrhea, currently or within 2 months before the first study dose, prior use of GSIs or other Notch-targeted agents, or any DT treatment within 4 weeks of screening.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.4-4"></a>

#### Registry exclusion criteria for Parts A and B: cardiac, laboratory, and prior treatment

> “Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥450 msec.”
> “Uncontrolled triglyceride ≥Grade 2 elevations per common terminology criteria for adverse events (CTCAE) v5.0 (>300 mg/dL or >3.42 mmol/L).”
> “Systemic therapy including chemotherapy, biologic (anti-neoplastic agent, antibodies), TKIs (e.g., sorafenib, pazopanib, imatinib), hormonal therapy, or investigational therapy”
> “Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose of IP”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.4-5"></a>

#### Open-label extension inclusion and exclusion criteria

> “Participated in Part A (including MRI at Week 16) and were still on study at time that Part B/OLE dose selection was made, OR”
> “Any participant with an ongoing TEAE (including abnormal laboratory results) from Part A or Part B that requires discontinuation from the study, will not be eligible to enter the open-label extension.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Randomization 1:1:1 to 1.2 mg once daily, 2 mg intermittent, or 4 mg intermittent

> “Participants were randomly assigned 1:1:1 to one of three oral varegacestat dose regimens: 1.2 mg once daily, 2 mg intermittent, or 4 mg intermittent (intermittent: once daily for 2 consecutive days with 5 consecutive days off).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.5-2"></a>

#### Rationale for intermittent dosing

> “Intermittent dosing was hypothesized to improve tolerability by mitigating GI toxicity observed with daily dosing in animal models.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.5-3"></a>

#### Treatment duration and switch to 1.2 mg once daily in the open-label extension

> “Participants received varegacestat at assigned doses until disease progression, intolerable toxicity, withdrawal of consent, or initiation of the open-label extension study (ie, after the last participant completed the week 16 MRI scan and the phase III dose was selected). At that time, participants still active in phase II were eligible to enter the open-label extension, where all received the selected phase III dose (1.2 mg once daily), regardless of their prior phase II dose assignment.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.5-4"></a>

#### Treatment beyond progression

> “Participants who experienced treatment benefit could continue on varegacestat after disease progression by blinded independent central review (BICR) with approval of the sponsor's medical monitor.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.5-5"></a>

#### Registry arms of Part A and the open-label extension

> “Experimental: Part A Main Study 1.2 mg daily”
> “Experimental: Part A Main Study 2 mg Intermittent”
> “Experimental: Part A Main Study 4 mg Intermittent”
> “AL102, recommended dose regimen from Part A, 1.2 mg daily”
> “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.5-6"></a>

#### Dose regimens: 2 mg and 4 mg on two days each week or 1.2 mg daily

> “The Phase 2 portion of RINGSIDE enrolled 42 participants at three different dosing regimens of varegacestat: 2 mg once a day for two days every week, 4 mg once a day for two days every week and 1.2 mg once a day daily.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint: safety based on treatment-emergent adverse events

> “The primary end point was safety of varegacestat based on treatment-emergent adverse events (AEs) coded according to the Medical Dictionary of Regulatory Activities (MedDRA) version 27.1. Investigators determined AE severity in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events v5.0 and assessed seriousness and relatedness to the study drug.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.6.1-2"></a>

##### Registry primary outcome: frequency and severity of TEAEs and SAEs

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Part A: Safety and Tolerability - Adverse Events” | “Evaluation of the safety and tolerability of AL102 in subjects with progressing desmoid tumors as defined by as defined by the frequency and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)” | “Approximately 1.5 years” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.6.1-3"></a>

##### Rationale: dose selection on safety and tolerability in a dose-finding study

> “Phase III dose selection was based on emerging safety and tolerability data after the last patient completed the week 16 magnetic resonance imaging (MRI) scan, and the key secondary end point of volume change could be assessed.”
> “Intermittent dosing was hypothesized to improve tolerability by mitigating GI toxicity observed with daily dosing in animal models.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.6.1-4"></a>

##### Adverse events of special interest: ovarian toxicity, liver enzyme elevations, and nonmelanoma skin cancers

> “Prespecified AEs of special interest were ovarian toxicity (MedDRA preferred terms amenorrhea, premature menopause, menopause, and ovarian failure), grade ≥2 elevations of ALT and AST, and nonmelanoma skin cancers.”
> “Prospectively evaluating reproductive function in GSI studies is important in the DT population with its predominance of women during childbearing years.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.6.1-5"></a>

##### Secondary endpoint: change in tumor volume from baseline to week 16 by BICR

> “The key efficacy evaluation was the secondary end point of change in tumor volume at week 16 compared with baseline, as measured by MRI and determined per BICR.”
> “Individual tumor volumes were derived using semiautomated three-dimensional segmentation by interpolating manually delineated tumor boundaries across contiguous slices and summing the segmented volumes after region-of-interest adjustments to ensure anatomic accuracy.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

| Outcome measure | Measure description | Time frame |
| --- | --- | --- |
| “Part A: Change in Tumor Volume” | “Change from baseline to Week 16 in tumor volume as measured by centrally read magnetic resonance imaging (MRI) by Blinded Independent Central Review (BICR)” | “Approximately 16 weeks” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.6.1-6"></a>

##### Rationale for volumetric MRI assessment

> “Because of nonuniform growth patterns of DT, volumetric measurements are more sensitive for early identification of response and outperform unidimensional assessment by RECIST v1.1”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

> “T2-weighted (T2W) signal intensity and tumor volume on MRI may be more sensitive than RECIST for assessing treatment effect in desmoid tumors (DTs)”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.6.1-7"></a>

##### Exploratory endpoints: RECIST v1.1 objective response rate, duration of response, and MRI signal biomarkers

> “Exploratory end points included ORR based on RECIST v1.1 performed both by the BICR and by the investigator, duration of response (DOR) by BICR and by the investigator, RECIST sum of diameters, T2-weighted signal intensity on MRI (an imaging biomarker to assess response and biological conversion from cellular, proliferative lesion to collagenous scar”
> “and degree of T1-weighted enhancement on postgadolinium MRI (an imaging biomarker that can help guide selection of optimal treatment strategies”
> “Baseline biopsies were assessed for CTNNB1 and APC mutations using the Tempus xT NGS assay (Tempus, Chicago, IL). Pharmacokinetic analyses evaluated varegacestat exposure across the three dose cohorts.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.6.1-8"></a>

##### Rationale for T2-weighted signal intensity as a marker of tumor cellularity

> “On T2W images, hyperintense areas are associated with active fibroblast proliferation and hypointense areas are associated with loss of tumor cells and an increase in collagenous tissue”
> “A decrease in T2 signal intensity, as measured by MRI, reflects a decrease in tumor cellularity and, in desmoid tumors, is considered an indicator of anti-tumor activity and symptomatic improvement.”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.6.1-9"></a>

##### Primary, secondary, and exploratory endpoints

> “Primary Endpoint: Safety”
> “Secondary Endpoint: Tumor volume reduction at Week 16”
> “Exploratory Endpoints: ORR by RECIST v1.1 and T2W signal reduction”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.6.1-10"></a>

##### Open-label extension endpoints in the registry

> “Open Label Extension (OLE): Safety and Tolerability”
> “OLE: Confirmed ORR”
> “Proportion of participants with confirmed ORR (CR and PR) by BICR based on RECIST v1.1”
> “OLE: PRO - GODDESS DTSS Total Symptom Score”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Sample size: 12 participants per dose regimen for 85% power

> “For the efficacy end point of change in tumor volume, 12 participants per dosing regimen provided 85% power to detect a statistically significant difference between week 16 and baseline measurements in each dosing regimen separately, assuming a standard deviation (SD) of 15 for tumor volume change (cm3), normally distributed tumor volume, an early discontinuation rate of 10%, and a t test with a two-sided alpha error of 5%.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.7.1-2"></a>

##### Participants enrolled, MRI-evaluable, and entering the open-label extension

> “In total, 42 participants enrolled in the randomized trial (14 per dose arm).”
> “Among the 37 (88.1%) MRI-evaluable participants in the randomized trial”
> “Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.7.1-3"></a>

##### Registry enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “198” |

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="topic-3.1.2.7.1-4"></a>

##### Evaluable population of 36 participants

> “Objective response per RECIST1 in evaluable patients (n=36)”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.7.1-5"></a>

##### Interim evaluable populations by dose regimen

> “The best response in the evaluable population as assessed by blinded independent central review (BICR) was partial response (PR) in 6/12 patients (50%) for 1.2 mg QD, 3/13 patients (23.1%) for 4 mg BIW, and 5/11 patients (45.5%) for 2 mg BIW.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Safety and efficacy analysis sets

> “Safety analyses included all randomly assigned participants who received at least one dose of varegacestat. Efficacy analyses included all randomly assigned participants who received at least one dose of varegacestat, had measurable disease assessed by BICR per RECIST v1.1 at baseline, and had a valid MRI measurement of tumor volume at week 4 or later.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.7.2-2"></a>

##### Analysis of covariance of tumor volume change and confidence intervals for response

> “Analysis of covariance (ANCOVA) for least squares (LS) mean change in tumor volume, SE, and 95% CI was performed with planned treatment as a fixed effect and baseline tumor volume and age as covariates. The median percent change from baseline in tumor volume at week 16 and the median best (minimum) percent change from baseline across all visits, including week 16, were evaluated for each dose arm.”
> “Two-sided 95% CI calculated using the Clopper-Pearson Exact Method.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.7.2-3"></a>

##### Evaluable population: at least one post-baseline scan

> “Evaluable population: patients with at least 1 post-baseline scan”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.7.2-4"></a>

##### Intention-to-treat and evaluable populations

> “Overall, the ORR in evaluable participants as measured by RECIST v1.1 by an independent radiologist was 64% for all doses tested. The 1.2 mg daily dosing cohort had an ORR of 75% in the evaluable population. Among participants in the intention-to-treat population, the overall response rate was 55% across all doses tested and the response rate was 64% for participants in the 1.2 mg daily dosing cohort.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.2.7.2-5"></a>

##### Subgroup analysis set: subgroups with at least 5 participants, pooled across dose regimens

> “We performed descriptive analyses of objective response rate (ORR) in the following subgroups with at least 5 participants: age (≤40 years vs. >40 years), tumor size (<70 mm vs. ≥70 mm), prior lines of therapy (0, 1, or 2+), tumor location (intra-abdominal vs. extra-abdominal) and mutational biomarkers (APC vs CTNNB1). Subgroups were analyzed by pooling across dose regimens.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-3.1.2.7.2-6"></a>

##### Post hoc imaging analysis methods

> “Descriptive analysis of T2W signal intensity, tumor volume and RECIST sum of diameters”
> “Linear correlations of best % changes from baseline on these assessments were evaluated with Pearson correlation coefficient”
> “Exposure-response modeling evaluated time course of drug effect on tumor volume to support selection of 1.2 mg once daily for further study”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Screening, enrollment, and discontinuation during the randomized trial

> “Between October 6, 2021, and July 15, 2022, 52 participants were screened, of whom 42 were enrolled (14 in each dose arm)”
> “Thirteen participants (31.0%) discontinued varegacestat for the following reasons: AE (n = 6), progressive disease (n = 3), withdrawal by the participant (n = 2), pregnancy (n = 1), and other reasons (n = 1).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.1-2"></a>

##### Exposure by dose arm during the randomized trial

> “Median varegacestat exposure was 50.5 (range, 3.0-76.0) weeks.”
> “The median (range) duration of varegacestat exposure during the randomized trial was 48.5 (7.0-69.0) weeks for the 1.2-mg once-daily dose, 52.0 (3.0-76.0) weeks for the 2-mg intermittent dose, and 48.5 (13.0-73.0) weeks for 4-mg intermittent dose.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.1-3"></a>

##### Open-label extension: 29 participants and 12 remaining on treatment as of January 6, 2025

> “Between October 4, 2022, and May 30, 2023, 29 (69.0%) participants transitioned to the open-label extension, where all received 1.2 mg once daily. As of January 6, 2025, 12 participants remained on treatment. The median duration of varegacestat exposure was 102.0 weeks (range, 3.0-169.0) for the combined randomized trial and open-label extension periods.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.1-4"></a>

##### Time on treatment as of January 6, 2025

> “42 participants enrolled”
> “29 (69%) entered the OLE”
> “Median time on treatment: 23.3 months (range 0.7 – 38.8)”
> “12 participants (29%) still on treatment”
> “Treatment duration: median 112 weeks | maximum: 165 weeks”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.8.1-5"></a>

##### Time on treatment as of April 10, 2024: median 25.4 months

> “Phase II enrolled 42 pts, of whom 29 (69%) entered the OLE. As of April 10, 2024, median time on treatment was 25.4 mo (range 1 – 29); 21 pts (50%) were still on treatment.”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.8.1-6"></a>

##### Time on treatment as of April 10, 2024: median 23.1 months

> “RINGSIDE Phase 2 enrolled 42 participants, of whom 29 (69%) entered the OLE. As of April 10, 2024, median time on treatment was 23.1 months (range 0.7 – 26.6) and 23 participants (55%) were still on treatment.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-3.1.2.8.1-7"></a>

##### Time on study as of January 3, 2023

> “As of January 3, 2023, median time on study was 10.5 months (range 0.8 – 14.7) and 30 patients (71.4%) were still on study, 10 (23.8%) of whom rolled over to the OLE.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Age, sex, mutation status, and prior therapy

> “Participant characteristics included 69.0% with prior systemic therapy, 47.6% with known CTNNB1 mutation, and 21.4% with known APC mutation (Table 1). The mean participant age was 39.9 (SD, 13.23) years, and 31 (73.8%) were female.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.2-2"></a>

##### Demographic and clinical characteristics by dose arm

| Characteristic | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “42.1 (11.32)” | “37.8 (14.76)” | “39.9 (13.99)” | “39.9 (13.23)” |
| Female, No. (%) | “11 (78.6)” | “9 (64.3)” | “11 (78.6)” | “31 (73.8)” |
| Women of childbearing potential, No. (%) | “9 (64.3)” | “7 (50.0)” | “7 (50.0)” | “23 (54.8)” |
| Intra-abdominal tumor at screening, No. (%) | “3 (21.4)” | “4 (28.6)” | “3 (21.4)” | “10 (23.8)” |
| Tumor volume at baseline by BICR, cm3, mean (SD) | “83.93 (92.280)” | “189.17 (368.846)” | “166.91 (211.038)” | “146.05 (242.664)” |
| CTNNB1 mutation, No. (%) | “8 (57.1)” | “4 (28.6)” | “8 (57.1)” | “20 (47.6)” |
| APC mutation, No. (%) | “2 (14.3)” | “5 (35.7)” | “2 (14.3)” | “9 (21.4)” |
| Prior systemic therapy, No. (%) | “9 (64.3)” | “13 (92.9)” | “7 (50.0)” | “29 (69.0)” |
| Prior surgery, No. (%) | “7 (50.0)” | “8 (57.1)” | “4 (28.6)” | “19 (45.2)” |
| Prior radiation therapy, No. (%) | “1 (7.1)” | “2 (14.3)” | “1 (7.1)” | “4 (9.5)” |
| Unidimensional tumor growth by ≥10% within 18 months of screening, No. (%) | “11 (78.6)” | “14 (100.0)” | “10 (71.4)” | “35 (83.3)” |
| Tumor-related pain not adequately controlled with nonopioid medicine, No. (%) | “5 (35.7)” | “5 (35.7)” | “5 (35.7)” | “15 (35.7)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.2-3"></a>

##### Median age, performance status, and median baseline tumor volume

| Characteristic | 1.2 mg once daily (n=14) | All doses (N=42) |
| --- | --- | --- |
| Age (years), median (min, max) | “44.0 (24, 61)” | “38.5 (19, 72)” |
| ECOG performance status 0, n (%) | “14 (100.0)” | “35 (83.3)” |
| ECOG performance status 1, n (%) | “0” | “7 (16.7)” |
| Intra-abdominal tumor at initial diagnosis, n (%) | “5 (35.7)” | “12 (28.6)” |
| Extra-abdominal tumor at initial diagnosis, n (%) | “9 (64.3)” | “30 (71.4)” |
| Tumor volume at baseline (cm3), median (min, max) | “46.30 (1.4, 244.9)” | “65.10 (1.4, 1270.3)” |

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.8.2-4"></a>

##### Median baseline tumor size by BICR

> “Tumor size at baseline by BICR, (mm)”
> “(17.0, 156.2)”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Tumor volume change at week 16 by dose arm

> “Among the 37 (88.1%) MRI-evaluable participants in the randomized trial, the median tumor volume reduction 16 weeks after starting 1.2 mg once daily (–51.91%) was numerically greater than that in the 2-mg (–15.25%) and 4-mg (–9.50%) intermittent regimens. In ANCOVA of LS mean tumor volume change from baseline to week 16, the reduction was statistically significant for the 1.2-mg once-daily dose (–39.8% [95% CI, –66.2 to –13.4]) but not for the 2-mg (–21.7% [95% CI, –52.0 to 8.6]) and 4-mg (–17.8% [95% CI, –43.2 to 7.6]) intermittent regimens.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-2"></a>

##### Median best percent change by dose arm during the randomized trial

> “The median best percent change from baseline was largest for 1.2 mg once daily based on tumor volume (–86.9%, –51.2%, and –63.4%), sum of diameters (–33.6%, –24.4%, and –26.3%), T2-weighted signal intensity (–90.0%, –53.4%, and –62.9%), and T1-weighted enhancement (–86.2%, –33.2%, and –54.2%; Fig 2).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-3"></a>

##### Confirmed objective response rate during the randomized trial

> “During the randomized trial, the confirmed ORR by RECIST v1.1 was 35.7% (five partial responses) for the 1.2-mg once-daily dose, 21.4% (three partial responses) for the 2-mg intermittent dose, and 21.4% (three partial responses) for the 4-mg intermittent dose (Table 3, upper half). The median time to response was 30.0, 40.3, and 51.0 weeks, respectively, and the Kaplan-Meier estimate of median DOR was not estimable. A total of 23 participants (54.8%) had stable disease (6, 10, and 7 participants, respectively).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-4"></a>

##### Tumor response by BICR per RECIST v1.1 during the randomized trial

| Response | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| Partial response, No. (%) | “5 (35.7)” | “3 (21.4)” | “3 (21.4)” | “11 (26.2)” |
| Stable disease, No. (%) | “7 (50.0)” | “6 (42.9)” | “10 (71.4)” | “23 (54.8)” |
| Progressive disease, No. (%) | “0” | “2 (14.3)” | “0” | “2 (4.8)” |
| Not available, No. (%) | “2 (14.3)” | “3 (21.4)” | “1 (7.1)” | “6 (14.3)” |
| Objective response 95% CI | “12.8 to 64.9” | “4.7 to 50.8” | “4.7 to 50.8” | “13.9 to 42.0” |
| Time to objective response, weeks, median (min, max) | “30.00 (17.3, 40.9)” | “40.29 (38.3, 41.0)” | “51.00 (40.3, 53.7)” | “40.29 (17.3, 53.7)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-5"></a>

##### Selection of 1.2 mg once daily for phase III

> “The 1.2-mg once-daily regimen was selected for phase III based on faster and larger decreases in tumor volume, sum of diameters, and T2-weighted signal intensity (Fig 3) and higher ORR than the intermittent regimens, with consistent safety and tolerability across all doses tested.”
> “The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-6"></a>

##### Pharmacokinetic exposure by dose regimen

> “Across all three regimens stratified by dose and visit, the median Tmax for varegacestat ranged from 1 to 2 hours postdose. The geometric mean plasma Cmax ranged from 10.9 to 19.6 ng/mL, from 11.9 to 24.3 ng/mL, and from 17.8 to 24.2 ng/mL across dose cohorts at week 0 day 1, week 0 day 2, and week 8 day 1, respectively (Appendix Table A2).”
> “The geometric mean week 8 day 1 to week 0 day 1 accumulation ratio for Cmax was 1.33, 1.71, and 1.19 for 1.2-mg once-daily, 2-mg intermittent, and 4-mg intermittent doses, respectively.”
> “Varegacestat exposure was comparable across the three regimens; however, response with the once-daily regimen suggests sustained exposure above a target threshold leading to better overall efficacy, indicative of the higher ORR observed, with a manageable toxicity profile.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-7"></a>

##### Open-label extension: tumor volume, sum of diameters, and T2-weighted signal by original dose arm

> “The median best percent changes from baseline by original randomized dose regimen, respectively, were –88.1%, –69.5%, and –88.9% for tumor volume, –51.9%, –34.9%, and –51.5% for sum of diameters, and –95.4%, –92.5%, and –97.0% for T2-weighted signal intensity.”
> “Among 29 (69%) participants who entered the open-label extension and received 1.2 mg once daily (median exposure, 102.0 [range, 3.0-169.0] weeks), the median best percent tumor volume change was –85.88% and the confirmed ORR increased to 57.1%.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-8"></a>

##### Open-label extension: confirmed objective response rate of 57.1%

> “During the open-label extension, 11 additional participants achieved a partial response and two achieved a complete response, resulting in 24 total responders for an overall ORR of 57.1%. The confirmed ORR increased from 35.7% to 57.1% in the original 1.2-mg once-daily arm, 21.4% to 50.0% in the original 2-mg intermittent arm, and 21.4% to 64.3% in the original 4-mg intermittent arm (Table 3, lower half). The median time to response was 37.7, 40.6, and 63.0 weeks, respectively, and the Kaplan-Meier estimate of median DOR was not reached across all original dose arms. Eleven participants (26.2%) continued to have stable disease.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-9"></a>

##### Tumor response by BICR per RECIST v1.1 in the randomized trial and open-label extension combined

| Response | Original 1.2 mg once daily (n = 14) | Original 2 mg intermittent (n = 14) | Original 4 mg intermittent (n = 14) | All (N = 42) |
| --- | --- | --- | --- | --- |
| Complete response, No. (%) | “0” | “1 (7.1)” | “1 (7.1)” | “2 (4.8)” |
| Partial response, No. (%) | “8 (57.1)” | “6 (42.9)” | “8 (57.1)” | “22 (52.4)” |
| Objective response, No. (%) | “8 (57.1)” | “7 (50.0)” | “9 (64.3)” | “24 (57.1)” |
| Objective response 95% CI | “28.9 to 82.3” | “23.0 to 77.0” | “35.1 to 87.2” | “41.0 to 72.3” |
| Time to objective response, weeks, median (min, max) | “37.71 (17.3, 65.1)” | “40.57 (28.1, 101.6)” | “63.00 (40.3, 121.3)” | “51.50 (17.3, 121.3)” |
| Duration of response, weeks, median (95% CI) | “NE (46.1 to NE)” | “NE (24.9 to NE)” | “NE (NE to NE)” | “NE (NE to NE)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.3-10"></a>

##### Exploratory imaging analysis: correlations and week 16 changes

> “A total of 25 responses were observed, of which one PR was unconfirmed”
> “T2W and volume demonstrated positive correlation with sum of diameters (R=0.67 and R=0.81, respectively)”
> “T2W and volume were highly correlated (R=0.93)”
> “Overall, median % changes at Week 16 were -8% by sum of diameters, -39% by T2W, and -24% by tumor volume”
> “Substantial early and rapid reductions in T2W signal intensity and tumor volume on MRI preceded subsequent varegacestat responses by RECIST in adults with DT”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.8.3-11"></a>

##### Exposure-response modeling: predicted median time to 30% tumor volume decrease of 3 months with 1.2 mg once daily

> “Predicted median time to 30% decrease in tumor volume was 3 months with the 1.2 mg once daily regimen”
> “Exploratory exposure-response modelling suggested that 1.2 mg once daily dose achieves earlier and deeper response than the other dose regimens”

Source: [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf)

<a id="topic-3.1.2.8.3-12"></a>

##### Objective response rate from 43% to 78% across subgroups

> “ORR ranged from 43% to 78% across age, tumor size, prior therapy, tumor location and mutation subgroups (Table). Response rates were comparable across all subgroups examined.”

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

| Subgroup | Responders, No. (%) |
| --- | --- |
| Age ≤40 years (n=22) vs. >40 years (n=14) | “13 (59) vs. 10 (71)” |
| Tumor size <70 mm (n=18) vs. ≥70 mm (n=14) | “13 (72) vs. 9 (64)” |
| Prior lines of therapy: 0 (n=11), 1 (n=16), or 2+ (n=9) | “6 (55), 10 (63), 7 (78)” |
| Intra-abdominal (n=9) vs. extra-abdominal (n=27) | “4 (44) vs. 19 (70)” |
| APC (n=7) vs CTNNB1 (n=19) mutation | “3 (43) vs. 13 (68)” |

Source: [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516)

<a id="topic-3.1.2.8.3-13"></a>

##### Objective response and duration of response by subgroup as of January 6, 2025

> “Data cutoff: Jan. 6, 2025”
> “ORR by RECIST ranged from 50% to 78%”
> “Median DOR ranged from 37.1 to 79.8 weeks”
> “Responses were seen in all subgroups examined”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

| Subgroup | ORR, n (%) | DOR, weeks, median (min, max) |
| --- | --- | --- |
| All MRI-evaluable patients (n=37) | “24 (65)” | “58.9 (12.1, 120.6)” |
| Age ≤40 years (n=22) | “13 (59)” | “66.1 (22.1, 110.0)” |
| Age >40 years (n=15) | “11 (73)” | “37.1 (12.1, 120.6)” |
| Tumor size <70 mm (n=19) | “10 (53)” | “52.1 (22.1, 99.0)” |
| Tumor size ≥70 mm (n=18) | “14 (78)” | “78.4 (12.1, 120.6)” |
| Prior lines of therapy 0 (n=11) | “6 (55)” | “79.8 (22.1, 95.9)” |
| Prior lines of therapy 1 (n=13) | “9 (69)” | “37.1 (12.1, 120.6)” |
| Prior lines of therapy 2+ (n=13) | “9 (69)” | “56.0 (12.1, 110.0)” |
| Intra-abdominal (n=10) | “5 (50)” | “46.1 (12.1, 99.0)” |
| Extra-abdominal (n=27) | “19 (70)” | “61.9 (12.1, 120.6)” |
| APC mutation (n=8) | “4 (50)” | “55.4 (12.1, 66.1)” |
| CTNNB1 mutation (n=19) | “13 (68)” | “79.6 (22.1, 120.6)” |
| CTNNB1 S45F (n=3) | “2 (67)” | “31.0 (24.9, 37.1)” |
| CTNNB1 T41A (n=5) | “2 (40)” | “88.2 (55.9, 120.6)” |
| CTNNB1 other (n=11) | “9 (82)” | “82.0 (22.1, 110.0)” |

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="topic-3.1.2.8.3-14"></a>

##### Objective response and median best change in tumor volume in the evaluable population

> “The median best change in tumor volume and T2 signal intensity (reduced tumor cellularity) were -88% for the 1.2 mg QD group and -85% for all patients, and -94% and -92%, respectively.”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

| Response | 1.2 mg QD dose (n=12) | All doses (n=36) |
| --- | --- | --- |
| Objective response rate (CR + PR), n (%) | “9 (75%)” | “23 (64%)” |
| Complete response, n (%) | “0 (0%)” | “2 (6%)” |
| Partial response, n (%) | “9 (75%)” | “21 (58%)” |
| Stable disease, n (%) | “3 (25%)” | “12 (33%)” |
| Progressive disease, n (%) | “0 (0%)” | “1 (3%)” |
| Disease control rate, n (%) | “12 (100%)” | “35 (97%)” |

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.8.3-15"></a>

##### Objective response in the evaluable and intention-to-treat populations

> “The 1.2 mg daily dosing cohort had an ORR of 75% in the evaluable population. Among participants in the intention-to-treat population, the overall response rate was 55% across all doses tested and the response rate was 64% for participants in the 1.2 mg daily dosing cohort.”
> “These data were reported in a poster presentation at ESMO in 2024.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.2.8.3-16"></a>

##### Interim partial response and tumor volume change at Week 16 and Week 28

> “The best response in the evaluable population as assessed by blinded independent central review (BICR) was partial response (PR) in 6/12 patients (50%) for 1.2 mg QD, 3/13 patients (23.1%) for 4 mg BIW, and 5/11 patients (45.5%) for 2 mg BIW. Disease control rate was 100%, 91%, and 97% in these groups, respectively.”
> “Median volume change (BICR) from baseline was -51.9% for 1.2 mg QD, -9.5% for 4 mg BIW, and -15.2% for 2 mg BIW at Week 16 and -76.4%, -35.5%, and -51.2%, respectively, at Week 28.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="topic-3.1.2.8.3-17"></a>

##### Interim partial response and tumor volume change at Week 16 and Week 28, rounded values

> “The best response in the evaluable population by blinded independent central review (BICR) was partial response in 6/12 pts (50%) for 1.2 mg QD, 3/13 pts (23%) for 4 mg BIW, and 5/11 pts (46%) for 2 mg BIW.”
> “Median volume change (BICR) from baseline was -52% for 1.2 mg QD, -10% for 4 mg BIW, and -15% for 2 mg BIW at Week 16 and -76%, -36%, and -52%, respectively, at Week 28, with similar patterns for T2 signal intensity (reduced tumor cellularity).”

Source: [Kasper et al. (2023)](https://doi.org/10.1016/j.annonc.2023.09.1158)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### Patient-reported outcomes not analyzed because of limited data and small samples

> “Analysis of patient-reported outcomes was precluded by limited data availability and small sample sizes.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.4-2"></a>

##### Registered open-label extension GODDESS outcome measures

> “OLE: PRO - GODDESS DTSS Total Symptom Score”
> “OLE: PRO - GODDESS DTSS Physical Functioning Domain Score”
> “OLE: PRO - WPI using GODDESS DTSS Item 1”

Source: [ClinicalTrials.gov NCT04871282](https://clinicaltrials.gov/study/NCT04871282)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Treatment-related adverse events: no grade 4 or 5 events and no treatment-related serious adverse events

> “Forty-one (97.6%) participants reported treatment-related adverse events (AEs), of which 9 (21.4%) reported grade 3 AEs and none reported serious AEs. There were no grade 4/5 events.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-2"></a>

##### Adverse events during the randomized trial: grade 3, serious, and most common events

> “Most AEs (96.5%) were grade 1 or 2. Grade 3 AEs were reported in 16 (38.1%) participants, and serious AEs were reported in six (14.3%) participants. No grade 4 or 5 AEs were reported. The most common AEs were diarrhea (81.0%), nausea (50.0%), and fatigue (42.9%). Most participants (97.6%) reported treatment-related AEs, of which three in each dose arm (9 of 42, 21.4%) reported treatment-related grade 3 AEs and none reported treatment-related serious AEs.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-3"></a>

##### Discontinuation because of adverse events by dose arm

> “The median time to treatment discontinuation because of an AE was 74.5 days for 1.2-mg once daily (four participants) and 55.5 days for 2-mg intermittent dosing (two participants). No participants on the 4-mg intermittent dose discontinued varegacestat because of an AE.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-4"></a>

##### Treatment-emergent adverse events during the randomized trial by dose arm

| Treatment-emergent adverse event, No. (%) | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| Any event | “14 (100.0)” | “14 (100.0)” | “14 (100.0)” | “42 (100.0)” |
| Treatment-related | “14 (100.0)” | “13 (92.9)” | “14 (100.0)” | “41 (97.6)” |
| Grade ≥3 | “5 (35.7)” | “7 (50.0)” | “4 (28.6)” | “16 (38.1)” |
| Treatment-related grade ≥3 | “3 (21.4)” | “3 (21.4)” | “3 (21.4)” | “9 (21.4)” |
| Serious | “1 (7.1)” | “4 (28.6)” | “1 (7.1)” | “6 (14.3)” |
| Leading to dose reduction | “6 (42.9)” | “0” | “5 (35.7)” | “11 (26.2)” |
| Leading to interruption | “11 (78.6)” | “5 (35.7)” | “7 (50.0)” | “23 (54.8)” |
| Leading to study drug withdrawal | “4 (28.6)” | “2 (14.3)” | “0” | “6 (14.3)” |
| Diarrhea | “14 (100.0)” | “8 (57.1)” | “12 (85.7)” | “34 (81.0)” |
| Nausea | “7 (50.0)” | “4 (28.6)” | “10 (71.4)” | “21 (50.0)” |
| Fatigue | “7 (50.0)” | “5 (35.7)” | “6 (42.9)” | “18 (42.9)” |
| Alopecia | “7 (50.0)” | “2 (14.3)” | “4 (28.6)” | “13 (31.0)” |
| Dry skin | “7 (50.0)” | “1 (7.1)” | “5 (35.7)” | “13 (31.0)” |
| Hypophosphatemia | “6 (42.9)” | “5 (35.7)” | “2 (14.3)” | “13 (31.0)” |
| Headache | “1 (7.1)” | “5 (35.7)” | “6 (42.9)” | “12 (28.6)” |
| Stomatitis | “7 (50.0)” | “2 (14.3)” | “3 (21.4)” | “12 (28.6)” |
| Amenorrhea | “4 (28.6)” | “3 (21.4)” | “4 (28.6)” | “11 (26.2)” |
| AST increased | “4 (28.6)” | “4 (28.6)” | “3 (21.4)” | “11 (26.2)” |
| Hot flush | “3 (21.4)” | “4 (28.6)” | “4 (28.6)” | “11 (26.2)” |
| Vomiting | “3 (21.4)” | “4 (28.6)” | “4 (28.6)” | “11 (26.2)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-5"></a>

##### Adverse events of special interest: liver enzyme elevations, cutaneous squamous cell carcinoma, and ovarian toxicity

> “Among AEs of special interest (Appendix Table A1, online only), grade ≥2 ALT/AST elevations were reported in four participants (9.5%)—two on the 2-mg intermittent dose and two on the 4-mg intermittent dose—and squamous cell carcinoma of the skin was reported in one participant (2.4%) on the 2-mg intermittent dose. Ovarian toxicity events, a known class effect of GSIs, were reported in 12 of the 23 women of childbearing potential (52.2%), including amenorrhea in four women on the 1.2-mg once-daily dose, three on the 2-mg intermittent dose, and four on the 4-mg intermittent dose, as well as premature menopause in one woman on the 1.2-mg once-daily dose. Among the 12 women who experienced ovarian toxicity, events resolved for six women (50%) and had not resolved at last follow-up for six women (50%).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-6"></a>

##### Adverse events of special interest by dose arm, appendix table

| Event, No. (%) | 1.2 mg once daily (n = 14) | 2 mg intermittent (n = 14) | 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| One or more adverse events of special interest | “6 (42.9)” | “5 (35.7)” | “5 (35.7)” | “16 (38.1)” |
| Amenorrhea | “3 (21.4)” | “3 (21.4)” | “4 (28.6)” | “10 (23.8)” |
| Premature menopause | “0” | “0” | “1 (7.1)” | “1 (2.4)” |
| Elevated liver enzymes (CTCAE grade ≥2) | “2 (14.3)” | “2 (14.3)” | “0” | “4 (9.5)” |
| Squamous cell carcinoma of skin | “1 (7.1)” | “0” | “0” | “1 (2.4)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-7"></a>

##### Open-label extension: five additional participants with treatment-related grade 3 adverse events

> “During continued varegacestat exposure at 1.2 mg once daily in the open-label extension, there were no grade 4 AEs, no deaths, no serious treatment-related AEs and five additional participants reported treatment-related grade 3 AEs (total, 14 participants [33.3%]; Appendix Table A3).”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-8"></a>

##### Treatment-emergent adverse events in the randomized trial and open-label extension combined

| Treatment-emergent adverse event, No. (%) | Original 1.2 mg once daily (n = 14) | Original 2 mg intermittent (n = 14) | Original 4 mg intermittent (n = 14) | All doses (N = 42) |
| --- | --- | --- | --- | --- |
| Grade ≥3 | “6 (42.9)” | “11 (78.6)” | “6 (42.9)” | “23 (54.8)” |
| Treatment-related grade ≥3 | “4 (28.6)” | “6 (42.9)” | “4 (28.6)” | “14 (33.3)” |
| Serious | “1 (7.1)” | “6 (42.9)” | “1 (7.1)” | “8 (19.0)” |
| Leading to dose reduction | “7 (50.0)” | “3 (21.4)” | “8 (57.1)” | “18 (42.9)” |
| Leading to interruption | “11 (78.6)” | “8 (57.1)” | “9 (64.3)” | “28 (66.7)” |
| Leading to study drug withdrawal | “4 (28.6)” | “4 (28.6)” | “1 (7.1)” | “9 (21.4)” |
| Diarrhea | “14 (100.0)” | “9 (64.3)” | “12 (85.7)” | “35 (83.3)” |
| Nausea | “8 (57.1)” | “5 (35.7)” | “10 (71.4)” | “23 (54.8)” |
| Fatigue | “8 (57.1)” | “6 (42.9)” | “8 (57.1)” | “22 (52.4)” |
| Hypophosphatemia | “7 (50.0)” | “5 (35.7)” | “3 (21.4)” | “15 (35.7)” |
| Stomatitis | “7 (50.0)” | “5 (35.7)” | “3 (21.4)” | “15 (35.7)” |
| Cough | “3 (21.4)” | “5 (35.7)” | “6 (42.9)” | “14 (33.3)” |
| Rash | “1 (7.1)” | “7 (50.0)” | “6 (42.9)” | “14 (33.3)” |
| Upper respiratory tract infection | “3 (21.4)” | “2 (14.3)” | “6 (42.9)” | “11 (26.2)” |

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.8.5-9"></a>

##### Safety summary and grade 3 or higher adverse events as of January 6, 2025

> “Data cutoff: Jan. 6, 2025”
> “8 pts (19%) had a serious adverse event (AE)”
> “9 pts (21%) discontinued due to an AE”
> “14 (33%) pts had treatment-related Grade 3 AEs”
> “No Grade 4-5 AEs”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

| Adverse event, n (%) | All grades (N=42) | Grade ≥3 (N=42) |
| --- | --- | --- |
| Diarrhoea | “35 (83.3)” | “5 (11.9)” |
| Nausea | “23 (54.8)” | “0” |
| Fatigue | “22 (52.4)” | “2 (4.8)” |
| Hypophosphatemia | “15 (35.7)” | “0” |
| Stomatitis | “15 (35.7)” | “1 (2.4)” |
| Cough | “14 (33.3)” | “1 (2.4)” |
| Headache | “14 (33.3)” | “0” |
| Rash | “14 (33.3)” | “0” |

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

<a id="topic-3.1.2.8.5-10"></a>

##### Updated safety: grade 3 drug-related TEAEs in 14 of 42 participants

> “The 5 most common Grade 1-2 treatment-emergent adverse events (TEAEs) were diarrhea, nausea, fatigue, headache and dry skin. Grade 3 drug-related TEAEs were reported in 14/42 (33%) pts, the most common being skin-related. There were no Grade 4-5 or serious drug-related TEAEs. No new safety signals were observed during long-term treatment.”

Source: [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857)

<a id="topic-3.1.2.8.5-11"></a>

##### Interim safety: grade 3 drug-related TEAEs in 26.2% of patients

> “Consistent with the mechanism of action of GSIs, the five most common Grade 1-2 treatment-emergent adverse events (TEAEs) were diarrhea, nausea, fatigue, alopecia, and dry skin. Grade 3 drug-related TEAEs were reported in 26.2% of patients across all tested doses. There were no Grade 4, Grade 5, or serious TEAEs related to AL102 per investigator assessment.”

Source: [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515)

<a id="topic-3.1.2.8.5-12"></a>

##### Interim safety: grade 3 drug-related TEAE in 10 of 42 patients

> “The 5 most common Grade 1-2 treatment-emergent adverse events (TEAE) were diarrhea, nausea, fatigue, alopecia, and dry skin. Grade 3 drug-related TEAE were reported in 10/42 (24%) pts. There were no Grade 4-5 or serious drug-related TEAE and no new safety signals.”

Source: [Kasper et al. (2023)](https://doi.org/10.1016/j.annonc.2023.09.1158)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

- RINGSIDE Part A was an open-label, randomized, dose-finding phase II study with 14 participants in each of three varegacestat dose regimens and no placebo or active comparator arm; the investigators describe it as having “small sample sizes and no placebo or active comparator arm”. The primary endpoint was safety; change in tumor volume at week 16 by BICR was the secondary endpoint, and RECIST v1.1 objective response rate was exploratory.
- The sample size was powered for the change in tumor volume from baseline within each regimen (12 participants per regimen, 85% power), so comparisons between regimens are descriptive: the LS mean reduction at week 16 was statistically significant for 1.2 mg once daily (–39.8%) and not for the 2 mg (–21.7%) or 4 mg (–17.8%) intermittent regimens. The efficacy analysis set (37 MRI-evaluable participants, 88.1%) excluded participants without measurable disease at baseline or a valid MRI at week 4 or later.
- The open-label extension switched all 29 continuing participants (69.0%) to 1.2 mg once daily between week 36 and week 76, so long-term results by original dose arm (confirmed ORR 57.1%, 50.0%, and 64.3%) reflect both the randomized regimen and later exposure to 1.2 mg once daily. Participants could continue varegacestat after progression by BICR with sponsor approval.
- Response rates differ by data cutoff and analysis population: an evaluable-population ORR of 75% for 1.2 mg once daily and 64% for all doses (April 10, 2024), an intention-to-treat ORR of 55% for all doses in the 10-K, and a confirmed ORR of 57.1% among all 42 participants as of January 6, 2025. Two abstracts with the April 10, 2024 cutoff report different median times on treatment (25.4 and 23.1 months), and two interim abstracts report grade 3 drug-related TEAEs in 26.2% (January 3, 2023 cutoff) and in 10 of 42 participants (24%).
- Subgroup analyses were post hoc, pooled across dose regimens, and limited to subgroups with at least 5 participants; the investigators state that “The sample sizes in each subgroup are relatively small”. The T2-weighted signal and exposure-response analyses were exploratory.
- Patient-reported outcomes were not analyzed because of “limited data availability and small sample sizes”. Ovarian toxicity had not resolved at last follow-up in 6 of 12 affected women. The study was sponsored by Immunome and Ayala Pharmaceuticals.

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725); [Kasper et al. (2024c)](https://doi.org/10.1016/j.annonc.2024.08.1857); [Chugh et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.11516); [Gounder et al. (2023b)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.11515); [Kasper et al. (2023)](https://doi.org/10.1016/j.annonc.2023.09.1158); [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf); [Gounder et al. (2025)](https://immunome.com/wp-content/uploads/2025/08/ASCO-2025-RINGSIDE-A-T2W-Poster.pdf); [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-3.1.2.9-2"></a>

#### Small sample sizes and no placebo or active comparator arm

> “RINGSIDE phase II was a dose-finding study with random assignment to three dose groups with small sample sizes and no placebo or active comparator arm. Analysis of patient-reported outcomes was precluded by limited data availability and small sample sizes. The ongoing RINGSIDE phase III trial is designed to confirm the clinical activity and safety profile and assess patient-reported outcomes, with once-daily varegacestat in a larger DT population.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

<a id="topic-3.1.2.9-3"></a>

#### Limitations of the post hoc subgroup analysis

> “This is a post hoc analysis of outcomes in different patient subgroups”
> “The sample sizes in each subgroup are relatively small”
> “We limited our analysis to subgroups with at least 5 patients”
> “The dosing regimen for patients on 2/4 mg intermittent changed to 1.2 mg once daily when they entered the OLE, per the study design”

Source: [Bui et al. (2025)](https://dtrf.org/wp-content/uploads/2025/12/UNBRANDED_CTOS_2025_RINGSIDE-A_Subgroups_POS_final.pdf)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
